Implication from thyroid function decreasing during chemotherapy in breast cancer patients: Chemosensitization role of triiodothyronine

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Huang, Jianbo ^a   Jin, Liangbin ^a   Ji, Guangyan ^a   Xing, Lei ^a   Xu, Chaobo ^a   Xiong, Xiong ^a   Li, Hongyuan ^a   Wu, Kainan ^a   Ren, Guosheng ^a   Kong, Lingquan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Chemotherapeutic efficacy; Non thyroidal illness syndrome; Thyroid hormones

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; LIOTHYRONINE; NAVELBINE; PACLITAXEL; THYROID HORMONE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; NON THYROIDAL ILLNESS SYNDROME; PREVALENCE; SIDE EFFECT; THYROID FUNCTION; ADOLESCENT; BLOOD; BREAST NEOPLASMS; COMPLICATION; DRUG EFFECTS; EUTHYROID SICK SYNDROMES; FLOW CYTOMETRY; MIDDLE AGED; THYROID DISEASES; THYROID GLAND; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EUTHYROID SICK SYNDROMES; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; THYROID DISEASES; THYROID GLAND; THYROID HORMONES; TRIIODOTHYRONINE; YOUNG ADULT;

EID: 84879812315     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-334     Document Type: Article

References (40)

1. Paulides M, Dorr HG, Stohr W, Bielack S, Koscielniak E, Klingebiel T, Jurgens H, Bolling T, Willich N, Sauer R, et al. Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System. Clin Endocrinol (Oxf) 2007, 66(5):727-731.
2. Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR. Thyroid function after treatment of brain tumors in children. J Pediatr 1991, 119(5):733-737. 10.1016/S0022-3476(05)80288-4, 1941379.
3. Willemse PH, Sleijfer DT, Sluiter WJ, Koops HS, Doorenbos H. Alterations in thyroid hormone metabolism during chemotherapy in patients with testicular carcinoma. Clin Endocrinol (Oxf) 1982, 16(3):303-313.
4. Hsieh TY, Hsu KF, Kuo PL, Huang SC. Uterine choriocarcinoma accompanied by an extremely high human chorionic gonadotropin level and thyrotoxicosis. J Obstet Gynaecol Res 2008, 34(2):274-278. 10.1111/j.1447-0756.2008.00770.x, 18412797.
5. Meister LH, Hauck PR, Graf H, Carvalho GA. Hyperthyroidism due to secretion of human chorionic gonadotropin in a patient with metastatic choriocarcinoma. Arq Bras Endocrinol Metabol 2005, 49(2):319-322.
6. Cooper DS. Hyperthyroidism. Lancet 2003, 362(9382):459-468. 10.1016/S0140-6736(03)14073-1, 12927435.
7. Majkowska-Mlynarczyk A, Kinalski M, Zaczek-Kucharska E. The thyroid gland function assessment in women after mastectomy and chemotherapy during breast cancer therapy. Endokrynol Pol 2007, 58(5):397-402.
8. Kumar N, Allen KA, Riccardi D, Bercu BB, Cantor A, Minton S, Balducci L, Jacobsen PB. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?. Breast Cancer Res Treat 2004, 83(2):149-159. 10.1023/B:BREA.0000010708.99455.e1, 14997046.
9. Conzemius MG, Graham JC, Haynes JS, Graham CA. Effects of treatment with growth hormone and somatostatin on efficacy of diammine [1,1-cyclobutane dicarboxylato (2-)-0,0']-(SP-4-2) in athymic rats with osteosarcoma. Am J Vet Res 2000, 61(6):646-650. 10.2460/ajvr.2000.61.646, 10850839.
10. Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, Li H, Shu XS, Liu W, Luo B, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res 2009, 69(12):5194-5201. 10.1158/0008-5472.CAN-08-3694, 19509237.
11. Barrera-Hernandez G, Park KS, Dace A, Zhan Q, Cheng SY. Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin/cyclin-dependent kinase levels and activity. Endocrinology 1999, 140(11):5267-5274. 10.1210/en.140.11.5267, 10537157.
12. Suhane S, Ramanujan VK. Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. Biochem Biophys Res Commun 2011, 414(1):73-78. 10.1016/j.bbrc.2011.09.024, 3207240, 21945435.
13. DeGroot LJ. "Non-thyroidal illness syndrome" is functional central hypothyroidism, and if severe, hormone replacement is appropriate in light of present knowledge. J Endocrinol Invest 2003, 26(12):1163-1170.
14. Rubenfeld S. Euthyroid sick syndrome. N Engl J Med 1978, 299(25):1414.
15. Jonckheer MH, Blockx P, Broeckaert I, Cornette C, Beckers C. 'Low T3 syndrome' in patients chronically treated with an iodine-containing drug, amiodarone. Clin Endocrinol (Oxf) 1978, 9(1):27-35.
16. Galton VA, Ingbar SH. Effect of a malignant tumor on thyroxine metabolism and thyroid function in the rat. Endocrinology 1966, 79(5):964-970. 10.1210/endo-79-5-964, 4162728.
17. Poth M, Tseng YC, Wartofsky L. Inhibition of TSH activation of human cultured thyroid cells by tumor necrosis factor: an explanation for decreased thyroid function in systemic illness?. Thyroid 1991, 1(3):235-240. 10.1089/thy.1991.1.235, 1668616.
18. Pang XP, Yoshimura M, Hershman JM. Suppression of rat thyrotroph and thyroid cell function by tumor necrosis factor-alpha. Thyroid 1993, 3(4):325-330. 10.1089/thy.1993.3.325, 8118227.
19. Nellen Hummel H, Gutierrez Espindola G, Talavera J, Gordon F, Halabe J, Flores G. Effect of chemotherapy on thyroid hormone concentration in patients with malignant hematologic diseases. Arch Med Res 1997, 28(2):215-217.
20. Kano T, Kojima T, Takahashi T, Muto Y. Serum thyroid hormone levels in patients with fulminant hepatitis: usefulness of rT3 and the rT3/T3 ratio as prognostic indices. Gastroenterol Jpn 1987, 22(3):344-353.
21. Kuijpens JL, Nyklictek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 2005, 15(11):1253-1259. 10.1089/thy.2005.15.1253, 16356089.
22. Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, Ohwada S, Morishita Y. Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer. Anticancer Res 1996, 16(4A):2069-2072.
23. Oosting SF, de Haas EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol 2010, 21(1):104-108. 10.1093/annonc/mdp265, 19605510.
24. Hershman JM. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab 2004, 18(2):249-265. 10.1016/j.beem.2004.03.010, 15157839.
25. Yoshimura M, Hershman JM. Thyrotropic action of human chorionic gonadotropin. Thyroid 1995, 5(5):425-434. 10.1089/thy.1995.5.425, 8563483.
26. Hershman JM. Hyperthyroidism induced by trophoblastic thyrotropin. Mayo Clin Proc 1972, 47(12):913-918.
27. Yoshimura M, Pekary AE, Pang XP, Berg L, Goodwin TM, Hershman JM. Thyrotropic activity of basic isoelectric forms of human chorionic gonadotropin extracted from hydatidiform mole tissues. J Clin Endocrinol Metab 1994, 78(4):862-866. 10.1210/jc.78.4.862, 8157712.
28. Higgins HP, Hershman JM, Kenimer JG, Patillo RA, Bayley TA, Walfish P. The thyrotoxicosis of hydatidiform mole. Ann Intern Med 1975, 83(3):307-311. 10.7326/0003-4819-83-3-307, 1180425.
29. Fisher PM, Hancock BW. Gestational trophoblastic diseases and their treatment. Cancer Treat Rev 1997, 23(1):1-16. 10.1016/S0305-7372(97)90017-7, 9189178.
30. Rajatanavin R, Chailurkit LO, Srisupandit S, Tungtrakul S, Bunyaratvej S. Trophoblastic hyperthyroidism: clinical and biochemical features of five cases. Am J Med 1988, 85(2):237-241. 10.1016/S0002-9343(88)80351-6, 2840826.
31. Kumar MS, Chiang T, Deodhar SD. Enhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems. Cancer Res 1979, 39(9):3515-3518.
32. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005, 103(6):1122-1128. 10.1002/cncr.20881, 15712375.
33. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, Stevens GH, Reddy SK, Peereboom DM, Elson PJ, et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003, 23(1B):617-626.
34. Richard GM, Gabriel NH, Thomas A. Neoplasms of the Breast. Cancer Medicine, Volume 2 2003, 1889. Frei: BC Decker, Donald WK, Raphaele P, Ralphr W, Robert CB, Ted SG, James FH, Emil F, 6.
35. Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 2009, 29(10):3825-3831.
36. Porlan E, Vega S, Iglesias T, Rodriguez-Pena A. Unliganded thyroid hormone receptor beta1 inhibits proliferation of murine fibroblasts by delaying the onset of the G1 cell-cycle signals. Oncogene 2004, 23(54):8756-8765. 10.1038/sj.onc.1208126, 15467737.
37. Cestari SH, Figueiredo NB, Conde SJ, Clara S, Katayama ML, Padovani CR, Brentani MM, Nogueira CR. Influence of estradiol and triiodothyronine on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors. Arq Bras Endocrinol Metabol 2009, 53(7):859-864. 10.1590/S0004-27302009000700010, 19942988.
38. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 2002, 21(5):761-768. 10.1038/sj.onc.1205136, 11850804.
39. Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, Luidens MK. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab 2009, 297(6):E1238-1246. 10.1152/ajpendo.00480.2009, 19755667.
40. Huang J, Ji G, Xing L, Li H, Wang Z, Ren G, Wu K, Kong L. Neo-endocrinochemotherapy: a novel approach for enhancing chemotherapeutic efficacy in clinic?. Med Hypotheses 2013, 80(4):441-446. 10.1016/j.mehy.2012.12.037, 23375412.